Brief: Gensight Biologics Secures €35 Million Credit Facility From EIB For Launch Of Lumevoq® In Europe

Gensight Biologics SA

04/11/2022 06:35

Nov 4 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS SECURES A €35 MILLION CREDIT FACILITY
FROM
THE EUROPEAN INVESTMENT BANK TO SUPPORT THE LAUNCH OF LUMEVOQ®
IN EUROPE
    * CREDIT FACILITY WILL ENABLE GENSIGHT TO SUPPORT
DEVELOPMENT OF
ITS PIPELINE AND IN PARTICULAR PREPARATION OF MARKETING OF
LUMEVOQ® IN EUROPE
    * CREDIT FACILITY CONSISTS OF THREE TRANCHES OF EUR 8
MILLION, EUR
12 MILLION, AND EUR 15 MILLION RESPECTIVELY, EACH REDEEMABLE IN
FINE IN 5 YEARS
    * THREE TRANCHES WILL BE AVAILABLE WITHIN 24 MONTHS
FOLLOWING
SIGNATURE OF FINANCE CONTRACT

Source text for Eikon:  ID:nBw1zYTkqa 
Further company coverage:  SIGHT.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))